secwatch.observer — SEC 8-K summary
======================================

Issuer:     PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)
CIK:        0001299130
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001299130-26-000076
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PacBio Q1 rev flat at $37.2M; consumable record but instrument miss; FY26 guidance $165-175M
--------------------------------------------------------------------------------

- Q1 revenue $37.2M flat YoY; consumable record $21.8M (+8% YoY), instrument revenue $9.7M (-12% YoY) below expectations.
- GAAP net loss $8.3M ($0.03/sh) vs $426.1M loss ($1.44/sh) in Q1 2025 (incl. restructuring); non-GAAP loss $35.9M ($0.12/sh).
- Full year 2026 revenue guidance $165M-$175M; cash $276M after $48.1M net from short-read asset sale.
- SPRQ-Nx beta to broad Revio launch in May; Basecamp Research project for ~100K samples selected PacBio.
- EMEA revenue +17% YoY; non-GAAP gross margin 37% vs 40% on component costs and promotions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1299130/000129913026000076/0001299130-26-000076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1299130/000129913026000076/pacb-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001299130-26-000076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer